Insmed

Forecast & Rating24 analysts currently cover Insmed, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $197.74, about 82.1% upside from the current price of $108.59. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 56.4% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Insmed closely still see room for the stock to rise. Data as of Sep 29, 2026; for reference only and not investment advice.